Small Dent in the Exelixis Armor

Motley Fool Rule Breakers pick Exelixis (Nasdaq: EXEL  ) isn't invincible after all. The drugmaker announced yesterday that one of its lead drugs failed in phase 2 testing. 

The drug, XL784, was in testing as a treatment for diabetic nephropathy, which is a form of kidney disease. No study details were released yesterday except that XL784 failed on the primary endpoint of reducing proteinuria (a by-product of abnormal kidney functioning).

XL784 is part of the basket of nine remaining drugs from which GlaxoSmithKline (NYSE: GSK  ) gets to choose up to three for further development. Because of the failed study, it's pretty unlikely that Glaxo will use one of its options on this drug. This was also the fate that Exelixis faced with oncology treatment XL647 earlier in the year, although another compound, XL880, may get picked up by Glaxo by December.

Only 20% of compounds entering phase 2 testing go on to regulatory approval, according to an oft-cited statistic from a Milken Institute policy brief. We'll find out the data on the failed XL784 study -- and what Exelixis plans to do with the compound once it has finished analyzing the data -- on Nov. 2, when Exelixis presents during the American Society of Nephrology Renal Week.

Sometimes drugs just don't work out like they're supposed to. Thankfully, Exelixis found this out in phase 2 testing rather than in a much more costly phase 3 trial. 

Read/Post Comments (0) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 538685, ~/Articles/ArticleHandler.aspx, 10/23/2016 6:24:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
EXEL $11.56 Down -0.18 -1.53%
Exelixis CAPS Rating: ****
GSK $41.13 Down -0.30 -0.72%
GlaxoSmithKline CAPS Rating: ***